Ostarine
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Best fit: preserving lean mass during a cut, recomping with modest strength/muscle gain, and adding a mild connective-tissue support layer.
Ostarine is mild only relative to stronger SARMs/AAS. At 15–50 mg/day it can suppress testosterone, distort SHBG/free T, and has published DILI case reports, so labs and an off-ramp matter.
Best fit: preserving lean mass during a cut, recomping with modest strength/muscle gain, and adding a mild connective-tissue support layer. It is often the entry-point SARM culturally, but the useful community range is still hormonally active.
Suppression is dose- and duration-dependent: low-dose short cycles may recover naturally, but 25 mg for 8–12 weeks and especially 50 mg protocols belong in a monitored SARM lane. Liver injury is uncommon but real in published case reports, and the article evidence supports ALT/AST, lipids, TT/FT, SHBG, LH/FSH, and symptom tracking rather than vibe-based recovery.
Ostarine earns its place when the goal is keeping muscle while dieting, smoothing joint discomfort, or trying a lower-tax SARM before LGD/RAD-style mass cycles. It is not a strong bulking tool; the article repeatedly shows a ceiling where more dose adds more endocrine tax faster than it adds clean anabolism.
High within community for muscle preservation and recomp; moderate for lean bulking. Generally rated below LGD-4033 and RAD-140 for raw mass. Preferred for first cycles, joint recovery, and female use.
Do not stack with aromatase inhibitors during cycle — AIs suppress the estrogen signal needed for HPG axis recovery and worsen suppression.
Intro
Ostarine (enobosarm, MK-2866, GTx-024) is the most extensively studied selective androgen receptor modulator (SARM) in existence.
It belongs to the arylpropionamide chemical class and is non-steroidal — unlike testosterone, it does not aromatize to estrogen and is not reduced by 5-alpha-reductase to DHT. These properties make it orally bioavailable without 17α-alkylation and free from estrogen-related side effects at most doses.
Developed by GTx Inc. beginning in the late 1990s, ostarine was initially investigated for cachexia, sarcopenia, stress urinary incontinence, Duchenne muscular dystrophy, and osteoporosis. By 2024, all of these indications had been abandoned after insufficient efficacy or adverse results in clinical trials. The only remaining active clinical development is a Phase II/III trial as a treatment for androgen receptor-positive, ER+, HER2-negative metastatic breast cancer in women (via Veru Healthcare). The compound has been on the WADA prohibited list since 2008 and is prohibited in all competitive sports.
Legal status: not approved for human use in any country; sold as a 'unregulated research-market compound' in gray-area markets globally. The compound is extensively used in bodybuilding, fitness, and athletic performance contexts despite the absence of regulatory approval. The gap between the clinical doses studied (1–18 mg/day) and community doses (25–50 mg/day) is pharmacologically significant — at community doses, ostarine behaves more like a mild androgen than a selective modulator.
The selectivity that makes ostarine appealing — tissue-specific anabolic action without androgenic side effects — is dose-dependent. At 1–6 mg/day (clinical range), selectivity is largely maintained. At 25–50 mg/day (community range), selectivity breaks down: HPG axis suppression becomes real, SHBG elevates dramatically, and prostate stimulation occurs. Community users are therefore working with a pharmacologically different compound than what clinical safety data describes.
Observed Effects
Lean muscle mass gain: clinical trial demonstrated 1.4 kg LBM increase at 3 mg over 12 weeks (ASCO 2007, Phase II, n=60); community at 25 mg over 8 weeks reports 2.5–7 lbs — dose-responsive relationship confirmed
Functional strength improvement: stair climbing power +25.5% at 3 mg in the 2007 clinical trial — functionally meaningful in elderly/cachectic population
Muscle preservation during caloric deficit: multiple community logs document complete muscle mass retention during aggressive cuts; one DEXA-confirmed log showed simultaneous +2.5 lb LBM gain + -2.3 lb fat over 8 weeks on lean bulk
5% total body fat reduction documented over an 8-week cut log using ostarine at moderate dose
Increased capillary density in muscle tissue (Henkies 2020, gastrocnemius + longissimus muscles, all three doses): better tissue oxygenation and nutrient delivery — may explain the 'pump all day' community observation
Connective tissue and joint healing: one of the most consistently reported community benefits; effective at 12.5–25 mg for joint/soft tissue support even in the absence of mass-building doses
Bone mineral density improvements: femoral trabecular density 26.01% vs 20.75% in orchiectomized controls (Böker 2023) when administered prophylactically; requires early use for trabecular benefit
Wellbeing, mood, and libido improvement during active cycle: multiple logs document increased alertness, improved mood, and enhanced libido as on-cycle secondary effects
Recovery enhancement: faster inter-session recovery is frequently reported across community logs as an underappreciated benefit
Myostatin mRNA paradoxically increased in rat gastrocnemius at anabolic doses (Naunyn-Schmiedeberg 2024) — may create a ceiling on muscle growth even at higher doses
Submaximal endurance decreased in male rat model at 8 weeks — counterproductive for endurance athletes
Muscle fiber size and type distribution not changed at any dose in the Henkies 2020 ovariectomized rat study — the vascularization and metabolic improvements do not translate to fiber hypertrophy in short-duration animal models
Coach Trevor experiment: 100 mg/day ostarine on TRT produced less effect than LGD or RAD-140 at equivalent doses — apparent ceiling on anabolic output even at extreme doses
Clinical trial failures across cachexia, DMD, stress incontinence — the compound did not perform sufficiently in most therapeutic indications
Field Reports
Early public logs established the core subjective pattern: fuller muscles, modest scale or recomposition changes, positive mood and pump during active use, and fewer obvious androgenic effects than classic AAS.
Later logs with objective body-composition or bloodwork data are more useful than hype reports. DEXA-style reports support modest lean-mass and fat-loss shifts, while post-cycle bloodwork reports show that real testosterone suppression can follow even cycles marketed as mild.
Injury-rehab and cut/recomp logs commonly frame ostarine as a muscle-preservation tool more than a dramatic muscle builder. That is the cleaner practical interpretation: it may help preserve lean mass and training output during a deficit, but expectations of steroid-like gains are usually misplaced.
Female community reports exist and are more common than for many SARMs, but they do not make ostarine a good default for women. The reported appeal is lower virilization pressure than other SARMs; the counterweight is still androgen-receptor activation, possible voice/hair/acne changes, menstrual or endocrine disruption, and better non-anabolic/longevity alternatives.
The overwhelming community pattern: ostarine often feels positive during active use, produces modest but real body-composition changes in responders, and can cause HPG suppression that requires bloodwork-guided recovery planning. The post-cycle experience without recovery planning is frequently the weak point.
Community Consensus
Ostarine occupies the 'gateway SARM' position in community culture — the compound users often describe as the first SARM experiment, the cautious alternative to AAS, or the lowest-friction recomp tool.
Its low perceived risk and once-daily oral use make it the dominant entry compound, but that reputation can understate real HPG suppression and lipid/liver monitoring needs.
The community dose has escalated dramatically over 15 years. Early public logs used lower ramps, later community protocols normalized 25 mg cycles, and recent high-dose discussions sometimes treat 50 mg/day as ordinary. That drift matters because selectivity and safety assumptions from low-dose clinical work should not be carried upward.
Is ostarine actually worth it? Advanced AAS users frequently conclude it is a 'poor man's steroid' — effective at its niche but producing nothing that a thoughtfully managed TRT or anavar cycle couldn't do better.
PCT or no PCT? Significant community disagreement. Higher-dose cycles are commonly paired with full recovery protocols, while lower-dose short cycles are often treated more casually. The article evidence shows suppression can occur even below the highest community ranges, so post-cycle planning should be driven by bloodwork and symptoms rather than community confidence.
Does ostarine cause hair loss? Community debate continues; documented cases often involve confounders, and the mechanism is unclear since ostarine bypasses 5-alpha-reductase.
SARMs as a class: a widely circulated community position frames SARMs as the cautious alternative to AAS — a stance in tension with the clinical trial landscape where virtually every SARM indication has been abandoned.
Product quality varies significantly in research-market settings; third-party identity and purity documentation are risk controls, not proof of medical legitimacy.
Risks & Monitoring
Testosterone suppression: real and confirmed at community doses. A community member's bloodwork (SARM community, 15 mg/12 weeks) showed TT 213 ng/dL (below range 280–800), FT 0.057 ng/mL (below range 0.090–0.30), SHBG 16.00 nmol/L (below range 18–54). LH and FSH at low-normal range.
SHBG elevation: ostarine dramatically and markedly elevates SHBG — multiple bloodwork reports confirm. This creates a paradox: SHBG elevation binds more circulating testosterone, reducing free T even while ostarine provides direct AR stimulation. Net androgenic effect may be lower than expected.
Competitive AR displacement: at 30 mg added on top of exogenous testosterone, a documented case reported a strength drop from 3 plates to 2 plates on squat — attributed to ostarine competing with testosterone for AR binding with a less intrinsically effective binding profile. Critical consideration for users on TRT.
HPTA suppression symptoms without PCT: fatigue, low libido ('zero sex interest for days'), sleepiness, reduced strength — documented at 3 weeks post-cycle without PCT intervention
Ostarine metabolized primarily in the liver (Taoussi 2024, LC-HRMS/MS + pooled human hepatocytes). Not 17α-alkylated, but hepatic processing still occurs.
Drug-induced liver injury (DILI): 15 case reports identified in systematic review (Vignali 2023), 7 cases with elevated ALT. Mean ALT elevation 7.1% above ULN. Cases associated predominantly with community doses. Most resolved on cessation.
One case of severe hepatocellular injury requiring hospitalization documented in the literature (Wen 2025 systematic review, n=970).
Liver panel monitoring (ALT, AST, bilirubin) recommended on-cycle, particularly at doses above 25 mg
Prostate stimulation at intermediate-high doses in male rats: prophylaxis dose (0.4 mg/kg) in orchiectomized rats restored prostate weight to near-intact levels (0.62 g vs 0.18 g control, vs ~0.65 g intact) — Böker 2023. Relevant for community doses where selectivity is lost.
Uterotrophic effect in female rats at 0.4 and 4 mg/kg (Henkies 2020) — off-target androgenic stimulation in female reproductive tissue at intermediate and high doses
Hair loss concern: one documented case of possible shedding at 12.5 mg in a finasteride user — mechanism unclear; may involve SHBG displacement of DHT or indirect androgen receptor effects in scalp
Blood pressure elevation: reported anecdotally in community users at higher doses; counterintuitive given ostarine's 'mild' framing
Accutane (isotretinoin) co-administration flagged as problematic: both compounds are hepatically processed; combination may increase liver strain risk
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establish pre-cycle TT and FT baseline; A documented post-cycle bloodwork case (SARM community) confirmed below-range TT (213 ng/dL) and FT at 3 weeks post-cycle — impossible to assess suppression without pre-cycle reference
Ostarine can meaningfully alter SHBG/free-testosterone interpretation — baseline SHBG is needed because TT alone can miss whether the user is functionally suppressed or binding more circulating androgen
Assess HPTA recovery post-cycle; a documented post-cycle panel (SARM community log) showed LH 1.90 mIU/mL (barely in range) and FSH 3.50 mIU/mL — these gonadotropin levels confirm the degree of pituitary suppression and guide PCT duration
Hepatic metabolism confirmed (Taoussi 2024); 15 DILI cases reported in literature; ALT elevation 7.1% above ULN documented in systematic review; liver enzymes should be checked at cycle midpoint, especially at doses above 25 mg
Oral SARMs can adversely affect lipid profiles; a bloodwork reviewer on a documented community log immediately flagged missing LDL/HDL; monitoring recommended at community doses
Post-PCT estradiol confirms recovery is not overshooting in the estrogenic direction; A post-cycle bloodwork case showed estradiol 16.52 pg/mL (in range, low end) at 3 weeks post-cycle without PCT — validates that estrogen rebound is not a primary concern with ostarine
Prostate stimulation documented at bodybuilder doses in animal models; men over 35 should establish PSA baseline; no PSA elevation noted at 3 mg clinical dose but community doses are 8–17× higher
General health monitoring; hematocrit elevation possible with androgenic activity at community doses; provides baseline for safety tracking
Avoid With
Do not combine Ostarine with the following. Sorted highest-severity first.
Why:Ostarine does not convert to estrogen (no aromatase activity). Adding an AI for PCT removes a non-existent target — crashing estrogen while doing nothing to stimulate LH/FSH recovery. Use SERMs (Nolvadex or Clomid) instead which act at the pituitary ER to restore gonadotropin production.
What to do:Documented: SARM community experienced moderators explicitly corrected multiple users planning this combination; a community user confirmed the same from personal bloodwork
Why:Community reports document strength decline when adding 30 mg ostarine to testosterone — attributed to competitive AR occupancy where ostarine (partial agonist) displaces testosterone from the receptor with a less efficacious binding profile. The net AR stimulus may decrease.
What to do:Lower ostarine doses (12.5–25 mg) appear to add to rather than compete with TRT; the competition effect emerged at 30 mg in the one documented case
Why:Ostarine would be overwhelmed by the stronger SARM and contribute nothing anabolically while adding its own suppressive burden. The combined suppression from stacking mismatched SARMs outweighs any theoretical additive benefit from ostarine's mild AR activity.
What to do:Sarmguide explicitly recommends against this; RAD-140 or LGD are the appropriate companions if stacking is desired
Why:Both compounds undergo significant hepatic processing. Concurrent use may compound liver strain, particularly at ostarine doses ≥25 mg where subclinical ALT elevation is documented.
What to do:Community consensus; no formal drug interaction studies exist; err on the side of separating use temporally
Protocols By Goal
Cut/recomp: 10–15 mg/day + GW-501516 10–20 mg/day for 8 weeks; caloric deficit 300–500 kcal. Ostarine is the anti-catabolic piece; Cardarine is the endurance/fat-oxidation piece and carries its own unresolved carcinogenicity baggage. A documented community approach (SARM community, 2020: 15 mg ostarine + 10 mg cardarine) produced visible abs and vascular recomposition over 12 weeks, but the same article evidence shows suppression can still appear after a 15 mg cycle.
Lean recomp: 25 mg/day for 8–12 weeks; maintenance to slight caloric surplus; some community protocols add GW-501516 20 mg/day throughout. DEXA-confirmed 8-week result: +2.5 lb LBM / -2.3 lb fat simultaneously on lean bulk. Plan post-cycle labs and likely PCT weeks 13–16 rather than assuming recovery.
High-dose experienced cut: 50 mg ostarine + 20 mg GW-501516 + N2Guard, 12 weeks; documented on community reports for users at 200+ lbs and 18–20% BF. Selectivity is lost at this dose — manage as a mild androgen, not a selective modulator.
Multi-SARM mass/recomp: LGD-4033 10 mg + ostarine 25 mg, both AM, weeks 1–12; add DGA POST CT weeks 9–12; Clomid 50/25/25/25 weeks 13–16; GW-501516 20 mg throughout. This is a canonical SARM community stack, but the LGD drives the tax and makes it a full suppressive cycle, not a beginner extension.
Low-complexity lean-mass stack: MK-677 25 mg/day + ostarine 20 mg/day for 8 weeks. MK-677 is non-suppressive, but ostarine is not; PCT decisions still depend on ostarine dose, duration, symptoms, and labs. Useful for SARM newcomers only if appetite/glucose effects from MK-677 and hormonal recovery from ostarine are both managed.
Joint/injury support: 12.5–25 mg/day for 8–12 weeks; no GW required; add liver support at higher doses. A community member (an anabolic discussion community, 2022) combined ostarine with test cyp for 4-month post-surgical knee recovery — the test base provides HPG stability while ostarine contributes connective tissue benefit.
Bridge/off-cycle use: 25 mg/day ostarine during the period between TRT protocols or off-cycle from TRT; documented to preserve muscle mass and maintain strength during exogenous testosterone withdrawal (a 2015 personal account). Note: at 30 mg on-TRT, community reports document AR competition causing strength loss — the 25 mg bridge appears more coherent off testosterone than on it.
AAS off-cycle support: 12.5–25 mg ostarine during AAS off-cycle to maintain muscle while HPG recovers. This is a tradeoff, not a free bridge: ostarine is lighter than AAS, but still exerts AR and HPG pressure.
Dosing Details
10–12.5 mg/day for 6–8 weeks
Conservative entry point; joint healing and muscle preservation benefits are the reason to stay here. Suppression risk is lower than 25–50 mg protocols, but it is not zero; use baseline and post-cycle labs before deciding that no PCT is needed.
25 mg/day for 8–12 weeks
Community standard as of 2015–2020 (SARM community protocols). Real suppression can develop at this dose × duration; mini-PCT (Nolvadex 20/20/10/10 or Clomid 50/25/25/25) is commonly used weeks 13–16 when post-cycle labs or symptoms justify it.
25 mg/day weeks 1–2, then 50 mg/day weeks 3–12
SARM community 2021 community protocol; 2025 community standard for experienced users. Adds N2Generate weeks 9–12 on-cycle; full PCT weeks 13–16; selectivity is largely absent at this dose range, so manage it like a mild androgen rather than a selective modulator.
5–12.5 mg/day for 6–8 weeks
Observed female community protocol: reports cluster around 5–12.5 mg/day for 6–8 weeks, with 12.5 mg/day often treated as a high-caution ceiling in those reports. PepTutor preserves this as observed female SARM use, not as a recommendation; any cycle changes, acne, hair changes, clitoral changes, or voice changes are stop signals.
12.5–25 mg/day for 8–12 weeks
Connective tissue benefit is reported at lower doses; there is no article-supported reason to push to 50 mg for joint-healing goals. Onset of joint relief is typically weeks 2–4.
Off-ramp rule: low-dose short cycles may recover without a SERM, but do not pre-decide that. Mini-PCT (Nolva 20/20/10/10) is the common 25 mg/12-week off-ramp; full PCT (Clomid 50/25/25/25 or Nolva 40/20/20/20) is the common 50 mg/12-week off-ramp. Never use aromatase inhibitors — no estrogen conversion occurs. Alternative on-cycle support patterns include enclomiphene 6.25–12.5 mg/day or HCG 125–250 IU/day, but those should be treated as separate hormone-management decisions and confirmed with bloodwork.
N2Guard throughout cycle (liver/organ support at doses ≥25 mg); N2Generate weeks 9–12 of 12-week cycle for hormonal support. Accutane co-administration should be avoided.
Stacks & Alternatives
The most universally recommended combination. Cardarine adds endurance enhancement and fat-oxidation without androgenic activity or suppression. GW-501516 at 20 mg is the community-standard add-on dose. Stack is especially effective for cutting/recomp. GW-501516 carries unresolved carcinogenicity concerns from rat studies — users should be aware of this risk
Most popular multi-SARM stack in the community. LGD provides the primary anabolic stimulus; ostarine adds connective tissue support and a mild secondary anabolic layer. LGD at 10 mg + ostarine at 25 mg is the canonical SARM community combination. Combined suppression is additive; full PCT required. Do not stack SARMs exceeding 8–12 weeks combined.
'Safe gains' beginner stack in community language, but only MK-677 is non-suppressive. MK-677 drives GH pulse frequency, appetite, and sleep quality; ostarine adds mild AR-mediated anabolism and still controls the PCT/lab question. MK-677 is not a SARM — it is a GH secretagogue; it adds glucose/appetite management rather than HPG suppression.
Moderately advanced combination. RAD-140 provides stronger anabolic stimulus than LGD with some neuroprotective properties; ostarine adds connective tissue and bone support. Not a beginner stack. RAD-140 is significantly more suppressive than ostarine; PCT must treat as if RAD-140 dose were the primary suppressor
Alternatives
Stack Cost
Moderate tax: ostarine is operationally simple and milder than LGD/RAD/AAS, but it still occupies a suppressive SARM lane once dose or duration moves beyond the low-dose joint/recomp range.
The article includes post-cycle community bloodwork with below-range total/free testosterone after 15 mg for 12 weeks, and repeatedly frames 25–50 mg cycles as requiring recovery planning.
Ostarine is not 17-alpha-alkylated, but hepatic metabolism and published DILI case reports justify ALT/AST monitoring. Lipids are a recommended check at community doses because oral SARM cycles can worsen HDL/LDL even when overt liver injury is absent.
Recommended panels include baseline TT/FT/SHBG, post-cycle LH/FSH and estradiol, mid-cycle ALT/AST and lipids, and PSA for older men. That is lighter than a heavy AAS cycle, but not casual.
The article preserves observed female ostarine reports at 5–12.5 mg while explicitly not recommending SARM use for women; pregnancy avoidance, menstrual tracking, and hard stop rules for voice or clitoral changes remain mandatory in any harm-reduction discussion.
The community dose drift from 10–20 mg toward 50 mg is the main tax escalator. At 25–50 mg the evidence indicates selectivity breaks down and the compound behaves more like a mild systemic androgen.
- ·Counts as a suppressive SARM lane for natural men once dose/duration reaches 25 mg for 8–12 weeks or higher.
- ·Low-dose joint/recomp use at 10–12.5 mg has more beginner margin, but still needs baseline and post-cycle labs before declaring recovery handled.
- ·Do not stack with LGD, RAD, YK-11, S23, oral AAS, or isotretinoin unless the combined suppression/liver/lipid burden is being managed as the primary cycle risk.
- ·On TRT, ostarine is not automatically additive; the article includes a 30 mg on-TRT strength-drop report consistent with possible AR competition.
- ·For women, do not recommend ostarine as a SARM/anabolic option; if discussing observed reports for harm reduction, keep the report range narrow (5–12.5 mg, 6–8 weeks), require no pregnancy possibility, and treat virilization or menstrual changes as immediate stop signals.
- ·Baseline and post-cycle hormone labs
- ·Mid-cycle liver enzymes and lipids for 25 mg+ or 12-week cycles
- ·PCT/off-ramp planning for 25–50 mg protocols
- ·Liquid-dose measurement discipline
- ·Female symptom tracking and pregnancy avoidance
Ostarine is intermediate: it is milder than LGD/RAD/AAS and operationally simple, but it still occupies a suppressive SARM lane where bloodwork, dose restraint, and an off-ramp matter.
- ·The user wants a 50 mg cycle, a multi-SARM stack, or a no-labs bridge.
- ·The user is trying to avoid all HPG-axis pressure.
- ·The user has active liver-risk signals or is combining it with other hepatically stressful compounds.
- ·The user is female and would ignore early voice, clitoral, acne, hair, or menstrual changes.
Practical Setup
Practical use should be framed as a suppressive SARM experiment, not a casual supplement trial. The lower community ranges are usually used for joint comfort, cutting, or preservation; higher community ranges are more suppressive and should be treated more like a mild androgen cycle than a selective-modulator trial.
Baseline and follow-up bloodwork are the core practical boundary: testosterone, SHBG, LH/FSH, liver enzymes, lipids, and symptoms determine whether recovery is actually handled. Aromatase inhibitors do not solve ostarine suppression because ostarine does not aromatize.
Effects are usually reported after the first 1-2 weeks, with the clearest value during a caloric deficit where muscle is maintained while fat comes off. Lean-bulk expectations should stay modest. Joint improvements are often the earliest noticed benefit.
Common failure modes: treating a short run as automatically suppression-free, skipping pre-cycle labs, confusing liquid concentration and volume, stacking with other hepatically stressful drugs, or using female reports to justify escalation despite virilization risk.
Mechanism Deep Dive
Ostarine is an arylpropionamide-class SARM that acts as a partial agonist at the androgen receptor (AR).
It binds the AR with high affinity and induces tissue-specific coactivator recruitment — in skeletal muscle, this activates anabolic gene programs; in certain androgen-sensitive tissues (prostate, seminal vesicles), activation is attenuated at low doses but normalizes at supraphysiologic doses. Unlike testosterone, it does not undergo aromatization to estradiol or 5-alpha reduction to DHT.
In myoblasts (C2C12 and L6 cell lines), ostarine stimulates AR signaling co-amplified through ERK1/2 kinase — pharmacological AR blockade completely eliminates the proliferative effect, confirming AR dependence (Leciejewska 2022, p<0.01). This AR/ERK1/2 co-activation upregulates myogenin, MyoD, and myosin heavy chain (MyH) — all three master transcription factors and structural markers of myogenic differentiation (p<0.01). In vivo: 30 days oral ostarine in rats produced increased myogenin/MyoD/MyH expression AND muscle mass increase (p<0.01), crossing the cell-line-to-animal gap.
In ovariectomized rats, all three ostarine doses (0.04, 0.4, 4 mg/kg/day) increased capillary density in gastrocnemius and longissimus muscles relative to both intact and control groups (Henkies 2020). This vascularization effect was stronger with ostarine than with LGD-4033. Importantly, muscle fiber size and type distribution were NOT changed — suggesting functional improvement is mediated via vascularization and metabolic enzyme activity rather than fiber hypertrophy at these doses.
Prophylactic ostarine prevents osteoporotic changes in cortical and trabecular bone. In orchiectomized male rats: femoral trabecular density 26.01% vs 20.75% in Orx controls; L4 vertebral trabecular density 16.3% vs 11.8% (Böker 2023). Therapy started 12 weeks after orchiectomy only improved cortical femoral density — trabecular benefits require early prophylactic administration. RANKL mRNA decreases with ostarine treatment (Komrakova 2018), suggesting reduced osteoclast activity as a mechanism.
SHBG belongs in the monitoring model because free testosterone can move differently from total testosterone during and after SARM exposure. The current article evidence supports tracking SHBG as an interpretive marker, but the exact direction and magnitude of ostarine's SHBG effect needs evidence-level review before it should be treated as a settled mechanism.
Myostatin mRNA paradoxically increased in gastrocnemius muscle of male Wistar rats at 8 weeks (Naunyn-Schmiedeberg 2024). Myostatin is a negative regulator of muscle growth — its upregulation may limit the compound's own anabolic ceiling. Submaximal endurance also decreased (maximal exhaustion time unchanged). These counterproductive effects at the rat anabolic dose range may explain the ceiling effect observed at 100 mg/day in human community reports.
Selectivity is not binary — it is dose-dependent. At 1–6 mg/day (clinical range), tissue selectivity is largely maintained: no PSA changes, no LH suppression documented in Phase II. At 25–50 mg/day (community range), the HPTA downregulates, prostate stimulation becomes more plausible, SHBG/free-testosterone interpretation becomes important, and the compound functions more like a mild systemic androgen. The clinical safety data cannot be extrapolated to community doses.
Half-life ~23.8 hours supports once-daily dosing. Hepatic metabolism is the primary site (Taoussi 2024); multiple metabolites identified by LC-HRMS/MS using negative electrospray ionization in pooled human hepatocytes. This hepatic processing is relevant to the DILI cases and supports liver enzyme monitoring.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
A Phase II clinical trial reported 1.4 kg lean body mass increase and 25.5% stair-climbing power improvement at 3 mg over 12 weeks.
Useful proof that low-dose ostarine can move lean-mass/function markers, but it should not be extrapolated directly to healthy bodybuilding users at 25–50 mg/day.
A DEXA-confirmed 8-week community log at 25 mg reported +2.5 lb lean body mass and -2.3 lb fat.
One of the stronger community datapoints for recomp, but still uncontrolled for training, diet, baseline status, and survivorship bias.
A community log using 15 mg ostarine with cardarine for 12 weeks showed post-cycle total testosterone 213 ng/dL, free testosterone below range, and low-normal LH/FSH three weeks after stopping without PCT.
Important because it shows suppression can occur below the 25–50 mg range; cardarine is not HPG-suppressive, so the recovery concern belongs to ostarine.
A systematic review identified 15 ostarine-associated DILI case reports, with 7 cases showing elevated ALT and most resolving after cessation.
Case reports cannot estimate incidence, but they justify liver-enzyme monitoring and avoiding concurrent hepatotoxic compounds.
In ovariectomized rats, ostarine increased capillary density in muscle at 0.04, 0.4, and 4 mg/kg/day, while uterotrophic effects appeared at 0.4 and 4 mg/kg/day.
Supports mechanism and female-specific caution, but animal dose translation is not direct enough to set human female dosing by itself.
In orchiectomized male rats, prophylactic ostarine improved femoral and vertebral trabecular density and restored prostate weight toward intact-control levels at 0.4 mg/kg.
Supports bone/prostate mechanism claims and the warning that tissue selectivity is dose-dependent; it is not direct proof of prostate outcomes in human community users.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.